The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …

Background Risk stratification and therapeutic decision-making for myelodysplastic
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), …

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1 , 2 . In patients with
myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease …

Background Patients with anemia and lower-risk myelodysplastic syndromes in whom
erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell …

The 2016 revision of the World Health Organization classification of tumors of hematopoietic
and lymphoid tissues is characterized by a closer integration of morphology and molecular …

Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase
disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study, pinometostat …

HIV causes a chronic infection characterized by depletion of CD4 + T lymphocytes and the
development of opportunistic infections. Despite drugs that inhibit viral spread, HIV infection …

Venetoclax with azacitidine (ven/aza) has emerged as a promising treatment regimen for
acute myeloid leukemia (AML), with a high percentage of clinical remissions in newly …

Identifying characteristics of patients who respond poorly to venetoclax-based therapy and
devising alternative therapeutic strategies for such patients are important topics in AML. We …

Targeting antiapoptotic proteins in AML is a key therapeutic strategy, and MCL1 is a critical
antiapoptotic oncoprotein. Armed with novel MCL1 inhibitors and the potent BCL2 inhibitor …